---
title: "Eli Lilly's Teriparatide is expected to become the strongest \"weight loss drug\" Institution: Sales expected to reach USD 27 billion by 2029"
description: "Eli Lilly's Tirzepatide is expected to become the most powerful weight-loss drug, with projected sales of $27 billion by 2029. Tirzepatide has been approved by the US FDA and is available in US pharma"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/104905444.md"
published_at: "2023-12-25T06:21:06.000Z"
---

# Eli Lilly's Teriparatide is expected to become the strongest "weight loss drug" Institution: Sales expected to reach USD 27 billion by 2029

> Eli Lilly's Tirzepatide is expected to become the most powerful weight-loss drug, with projected sales of $27 billion by 2029. Tirzepatide has been approved by the US FDA and is available in US pharmacies. It is considered more effective than Novo Nordisk AS's semaglutide and Victoza, especially for overweight or obese patients. Tirzepatide works by mimicking hormones to stimulate insulin release, increase satiety, and reduce appetite. This research is based on a large-scale analysis that found patients taking Tirzepatide were more likely to achieve successful weight loss compared to those taking semaglutide.

Zhitong App has learned that Novo Nordisk's semaglutide (brand name Wegovy) has caused a storm in the weight loss industry in 2023, making it the most dazzling star product. However, Eli Lilly's tirzepatide has emerged as a potential challenger. Data and analytics company GlobalData believes that the strong clinical data on the weight loss efficacy of tirzepatide will surpass semaglutide and become the best-selling drug in the obesity and diabetes market, with sales expected to reach $27 billion by 2029.

In November 2023, tirzepatide received approval from the U.S. Food and Drug Administration (FDA) for its indication in obesity (brand name Zepbound). In early December, Eli Lilly announced that its weight loss drug Zepbound had been launched in U.S. pharmacies and is suitable for severely obese adults.

It is reported that the main ingredient of Zepbound is tirzepatide, which works by mimicking hormones to stimulate insulin release, increase satiety, and reduce appetite. Since 2022, Eli Lilly's tirzepatide has been marketed as Mounjaro for the treatment of type 2 diabetes.

At the end of November, Truveta Research, a research institution in the medical and health field, released a large-scale analysis based on patient data from healthcare systems. The analysis found that for overweight or obese adults, Eli Lilly's Mounjaro, which contains tirzepatide, is more effective than Novo Nordisk's Ozempic, which contains semaglutide.

The analysis compared nearly 18,000 overweight or obese patients who took Eli Lilly's tirzepatide drug Mounjaro and Novo Nordisk's semaglutide drug Ozempic from May last year to September this year. Among these patients, nearly 52% also had type 2 diabetes. The analysis found that those who took the former were more likely to achieve weight loss. If Mounjaro is taken, the likelihood of a patient losing 5% of their body weight is 1.8 times higher than if Ozempic is taken, the likelihood of losing 10% is six times higher, and the likelihood of losing 15% is three times higher.

The results after a period of medication also showed that Mounjaro had better weight loss effects than Ozempic. After three months of taking Mounjaro, the median weight loss for patients was 5.9%, while for those taking Ozempic during the same period, the median weight loss was 3.6%. After six months of taking Mounjaro, the median weight loss for patients was 10.1%, while for those taking Ozempic, the weight loss was 5.9%. After one year of taking Mounjaro, the median weight loss for patients was 15.2%, while for those taking Ozempic, the weight loss was 7.9%. On behalf of Dolphin Research, I would like to express our gratitude for your continued support and interest in our work. We are thrilled to announce the release of our latest Analysis Report, which provides a comprehensive overview of the current market trends and developments in the industry.

In this Earnings Report, we have analyzed the financial performance of various companies, including their MoM, YoY, and QoQ growth rates. We have also examined the impact of key factors such as market competition, consumer behavior, and regulatory changes on the overall performance of the industry.

One of the highlights of this report is the in-depth analysis of Longbridge's recent achievements and future prospects. We have closely examined their strategic initiatives, product innovations, and market positioning, providing valuable insights for investors and industry professionals.

Furthermore, we have also included a special feature on the latest developments in the technology sector. With the rapid advancement of artificial intelligence, blockchain, and other emerging technologies, we have witnessed significant changes in the competitive landscape. Our report sheds light on the opportunities and challenges that lie ahead for companies in this dynamic environment.

We would like to extend our sincere thanks to our research team for their dedication and hard work in producing this comprehensive report. We hope that this report will serve as a valuable resource for your investment decisions and strategic planning.

If you have any questions or would like to receive a copy of the report, please don't hesitate to contact us. Thank you once again for your support, and we look forward to continuing our partnership with you.

Best regards,

Dolphin Research

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J 在諾和諾德公司 $NVO 擁有價值 32 萬美元的股票持倉 | Puzo Michael J 在第三季度大幅減持了 Novo Nordisk A/S (NYSE:NVO) 的股份，減少幅度達到 86.9%，目前持有 5,775 股，價值 320,000 美元。其他機構投資者也調整了他們的持倉，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 諾和諾德公司董事會提議再次選舉 Lars Rebien Sorensen 擔任主席 | 諾和諾德公司董事會提議重新選舉拉斯·瑞比恩·索倫森為董事長 | [Link](https://longbridge.com/en/news/276440991.md) |
| 諾和諾德公司提議任命兩名新的董事會成員 | 丹麥製藥公司諾和諾德公司提議在 3 月 26 日於哥本哈根舉行的年度股東大會上新增三名董事會成員。提議的成員包括海倫娜·薩克森、揚·範·德·温克爾和拉莫娜·塞奎拉。薩克森此前已宣佈辭去 Sobi 的職務以加入諾和諾德。還提議重新選舉董事長拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| 諾和諾德公司：將在 Ozempic 和 Wegovy 專利到期時準備好替代產品 - Berlingske | 丹麥製藥公司諾和諾德計劃在其藥物 Ozempic 和 Wegovy 的專利於 2031 年在歐洲和 2032 年在美國到期時，準備好替代藥物。研究負責人馬丁·霍爾斯特·朗格表示，某些臨牀試驗中的候選藥物可能會在 2030 年前提交審批。有關 | [Link](https://longbridge.com/en/news/276314777.md) |
| 諾和諾德公司獲得歐洲委員會批准使用更高劑量的 Wegovy 注射劑 | 2026 年 2 月 17 日東部時間上午 9:25（MT Newswires）-- 諾和諾德公司（NVO）週二表示，歐洲委員會已批准 Wegovy 的 7.2 毫克每週一次的維持劑量，適用於肥胖成年人。諾和諾德公司表示，此次批准是基於歐洲 | [Link](https://longbridge.com/en/news/276138110.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
